<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04808310</url>
  </required_header>
  <id_info>
    <org_study_id>2020-15296</org_study_id>
    <nct_id>NCT04808310</nct_id>
  </id_info>
  <brief_title>QUantitative Flow Ratio Or Angiography for the assessMent of nOn-culprit Lesions</brief_title>
  <acronym>QUOMODO</acronym>
  <official_title>QUantitative Flow Ratio Or Angiography for the assessMent of nOn-culprit Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to study whether the use of complex 3-dimensional assessment of the&#xD;
      severity of a stenosis improves angina and in general cardiovascular outcomes in patients who&#xD;
      have residual intermediate coronary artery stenosis following an acute coronary syndrome&#xD;
      (ACS) treated with percutaneous coronary intervention (PCI).&#xD;
&#xD;
      Goals of the study are:&#xD;
&#xD;
        -  To investigate whether decision-making based on quantitative flow reserve (QFR) is&#xD;
           associated with a decrease in angina 3 months after an ACS&#xD;
&#xD;
        -  To investigate whether use of QFR is associated with an improved prognosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a single-center, randomized superiority trial to compare two strategies for the&#xD;
      assessment of the hemodynamic relevance of coronary lesions.&#xD;
&#xD;
      The primary analysis will be on the per-protocol principle (i.e. including all patients who&#xD;
      are not protocol violators). A separate analysis will be performed on an intention-to-treat&#xD;
      basis (i.e. all randomized patients randomized to a treatment arm).&#xD;
&#xD;
      Primary endpoint 1. Angina questionnaire&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
      Number and % of patients undergoing PCI&#xD;
&#xD;
      Seattle Angina Questionnaire&#xD;
&#xD;
        -  SAQ Physical limitation scale&#xD;
&#xD;
        -  SAQ angina stability scale&#xD;
&#xD;
        -  SAQ angina frequency scale&#xD;
&#xD;
        -  SAQ quality of life&#xD;
&#xD;
        -  SAQ Treatment Satisfaction Disease perception scale Follow-up (3 and 12 months) -&#xD;
           Patient-oriented composite endpoint (death, myocardial infarction, unplanned&#xD;
           revascularization) and its components.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Anticipated">March 17, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 17, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized 1:1 to one of the two study arms. Randomization will be done by using a computer-generated random sequence (Medcalc, Mariakerke, BE).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Patients and outcome assessors will be blinded to the randomization group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Seattle angina questionaire summary score</measure>
    <time_frame>3 months</time_frame>
    <description>change in angina severity as assessed by the Seattle Angina Questionnaire (SAQ, score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life))</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seattle angina questionaire summary score</measure>
    <time_frame>12 months</time_frame>
    <description>change in angina severity as assessed by the Seattle Angina Questionnaire (SAQ, score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients undergoing PCI</measure>
    <time_frame>1 day</time_frame>
    <description>Decision to perform PCI based on angiography versus QFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-oriented composite endpoint</measure>
    <time_frame>3 months</time_frame>
    <description>Patient-oriented composite endpoint (death, myocardial infarction, unplanned revascularization).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-oriented composite endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Patient-oriented composite endpoint (death, myocardial infarction, unplanned revascularization).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Angiography</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The indication to further coronary intervention will be based on angiographic diameter stenosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quantitative flow ratio (QFR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The indication to further coronary intervention will be based on QFR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Quantitative flow ratio</intervention_name>
    <description>Quantitative flow ratio (QFR) is a computer method that estimates the hemodynamic relevance of a coronary stenosis based on three-dimensional quantitative coronary angiography (3D QCA)</description>
    <arm_group_label>Quantitative flow ratio (QFR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Assessment of angiographic severity of the stenosis</intervention_name>
    <description>The indication to coronary stent intervention will be based on angiography</description>
    <arm_group_label>Angiography</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Successfully treated acute coronary syndrome&#xD;
&#xD;
          -  At least one additional intermediate stenosis (&gt;20% and &lt;75%).&#xD;
&#xD;
          -  Patient â‰¥18 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stenoses or patients a priori not amenable to treatment with PCI (at the discretion of&#xD;
             two interventional cardiologists - e.g. patients with limited life expectancy,&#xD;
             stenosis in very small vessels, very diffuse disease with complex/very calcified&#xD;
             stenosis requiring surgery etc).&#xD;
&#xD;
          -  Persistent symptoms or evidence of ischemia requiring intervention of the non-culprit&#xD;
             lesion.&#xD;
&#xD;
          -  Any contraindication to PCI according to guidelines&#xD;
&#xD;
          -  An ACS in the period following the index ACS and randomization&#xD;
&#xD;
          -  TIMI (Thrombolysis in Myocardial Infarction) flow grade &lt; 3 in the culprit vessel&#xD;
&#xD;
          -  Presence of thrombus in the non-culprit lesion&#xD;
&#xD;
          -  Participation in another randomized interventional study interfering with the present&#xD;
             protocol&#xD;
&#xD;
          -  Patient unable to give informed consent&#xD;
&#xD;
          -  Women of child-bearing potential or lactating&#xD;
&#xD;
          -  Previous coronary artery bypass surgery CABG&#xD;
&#xD;
          -  Recent (within 30 days) unsuccessful PCI&#xD;
&#xD;
          -  Decompensated congestive heart failure (CHF) or hospitalization due to CHF during the&#xD;
             last 3 months&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt;30%&#xD;
&#xD;
          -  Severe chronic obstructive pulmonary disease (COPD)&#xD;
&#xD;
          -  Severe valvular heart disease&#xD;
&#xD;
          -  FFR (or RFR, iFR etc) assessment of non-culprit lesions at the time of the index&#xD;
             procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Center of Cardiology, Cardiology I, university hospital Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tommaso Gori, Prof Dr, PhD</last_name>
      <phone>+49 (0) 6131 17 2729</phone>
      <email>tommaso.gori@unimedizin-mainz.de</email>
    </contact>
    <investigator>
      <last_name>Tommaso Gori, Prof Dr, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>Tommaso Gori</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

